Trump Ends $2 Copay For Seniors, Sparks Fears Of Rising Drug Costs

acf/google-ad-placement

Scienture Holdings, Inc. SCNX shares initially traded higher on Tuesday but have since reversed after the Food and Drug Administration (FDA) approved its <a href="https://www.benzinga.com//node/44374406">new drug application for Arbli.</a>



What To Know: Arbli (losartan potassium) is first and only FDA approved ready-to-use oral liquid losartan available in the United States.



It is designed to treat hypertension in patients over 6 years old, reduce stroke risk in patients with hypertension and left ventricular hypertrophy and treat diabetic nephropathy in certain patients with type 2 diabetes.



&#8220;We are pleased to bring to market, Arbli, a transformative therapy option containing losartan, one of the most widely prescribed molecules in its class, to patients, caregivers and healthcare professionals. We expect to commercially launch and make Arbli&nbsp;available to patients in the U.S. in&nbsp;Q3&nbsp;2025,&#8221; said Narasimhan Mani, President of Scienture.



See Also: <a href="https://www.benzinga.com/25/03/44378672/defense-stocks-are-soaring-expert-sees-170-as-achievable-by-year-end-for-this-preferred-pick">EXCLUSIVE: This Defense Stock Could Hit $170 &#8216;Before Year-End,&#8217; Expert Explains Why</a>



SCNX Price Action: At the time of writing, Scienture stock is trading 16.5% lower at $2.07, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.



Image: via Shutterstock

News

Movers

Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company announced the FDA approved its new drug application for Arbli.

Application error: a client-side exception has occurred (see the browser console for more information).